Importantly, anti-pentraxins drugs (CPHPC and dezamizumab) targeting human SAP have recently entered in clinical phase 2 trial for treatment of amyloidosis and Alzheimer's disease, and human CRP inhibitor targeting CRP-driven complement activation-mediated tissue damage is also being developed (62). This evidence concerns the gene CRP and early-onset autosomal dominant Alzheimer disease.